GSK’s Nucala Gains Approval in China for CRSwNP

Date:

https://www.tipranks.com/news/company-announcements/gsks-nucala-gains-approval-in-china-for-crswnp

GlaxoSmithKline ( (GSK) ) has provided an update.

GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval marks the third indication for mepolizumab in China and offers patients a non-surgical treatment alternative to systemic corticosteroids and surgery. The approval is based on successful trials demonstrating its efficacy and safety, positioning GSK as a leader in addressing type 2 inflammation-related diseases.

More about GlaxoSmithKline

GSK is a global biopharmaceutical company dedicated to combining science, technology, and talent to advance healthcare. It has a leading respiratory portfolio and is committed to improving treatments and outcomes for people with respiratory diseases such as asthma, COPD, chronic cough, and rarer conditions, aiming to modify and prevent disease progression.

YTD Price Performance: 0.0%

Average Trading Volume: 5,830,724

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $68.81B

See more data about GSK stock on TipRanks’ Stock Analysis page.

Share post:

Popular

More like this
Related

Arsenal vs Newcastle prediction: Semi-final stalemate

Arsenal vs Newcastle betting tipsMatch to end in a...

LSU basketball fans turn up for ‘Dress Like Kim Mulkey Day’

LSU women's basketball coach Kim Mulkey has made a...

Nippon, US Steel file suit after Biden administration blocks $15 billion deal

WASHINGTON (AP) — Nippon Steel...